Clin Exp Vaccine Res.  2013 Jul;2(2):83-91. 10.7774/cevr.2013.2.2.83.

BCG vaccine in Korea

• Joung SM
• Ryoo S

• KMID: 2167717
• DOI: http://doi.org/10.7774/cevr.2013.2.2.83

Abstract

The anti-tuberculosis Bacille de Calmette et Guerin (BCG) vaccine was developed between 1905 and 1921 at Pasteur Institutes of Lille in France, and was adopted by many countries. BCG strains comprise natural mutants of major virulence factors of Mycobacterium tuberculosis and that BCG sub-strains differ markedly in virulence levels. The tuberculosis became endemic in Korea after the Korean War (1950s). The BCG strain, which was donated by Pasteur Institutes, was brought to Korea in 1955, and the first domestic BCG vaccine was produced by the National Defense Research Institute (NDRI), current Korea Centers for Disease Control and Prevention (KCDC), in 1960. Since 1987, BCG manufacture work was handed over to the Korean Institute of Tuberculosis (KIT), the freeze-dried BCG vaccine was manufactured at a scale required to meet the whole amount of domestic consumption. However, since 2006, the manufacture of BCG vaccine suspended and the whole amount of BCG was imported at this point of time. Now KIT is planning to re-produce the BCG vaccine in Korea under the supervision of KCDC, this will be render great role to National Tuberculosis Control Program (NTP) and provide initiating step for developing new tuberculosis vaccines in Korea.

Keyword

BCG vaccine; Korea; Tuberculosis

MeSH Terms

Academies and Institutes
BCG Vaccine
Centers for Disease Control and Prevention (U.S.)
France
Hand
Korea
Korean War
Mycobacterium bovis
Mycobacterium tuberculosis
Organization and Administration
Sprains and Strains
Tuberculosis
Tuberculosis Vaccines
Virulence Factors
BCG Vaccine
Tuberculosis Vaccines
Virulence Factors

Figure

• 

  Fig. 1 Refined genealogy of BCG vaccines, modified from Liu et al. [10]. M. bovis, Mycobacterium bovis; BCG, Bacillus de Calmette et Guérin; RD, region of difference.

Reference

1. Madkour MM, Warrell DA. Tuberculosis. Berlin: Springer;2004.

2. Zink AR, Sola C, Reischl U, et al. Characterization of Mycobacterium tuberculosis complex DNAs from Egyptian mummies by spoligotyping. J Clin Microbiol. 2003; 41:359–367.

3. Calmette LC, Guérin C, Weill-Hallé B. Essais d'immunisation contre l'infection tuberculeuse. Rev Tuberc. 1924; 5:481–491.

4. Bannister C, Bennett L, Carville A, Azzopardi P. Evidence behind the WHO guidelines: hospital care for children: what is the evidence that BCG vaccination should not be used in HIV-infected children? J Trop Pediatr. 2009; 55:78–82.

5. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec. 2004; 79:27–38.

6. Behr MA, Small PM. Has BCG attenuated to impotence? Nature. 1997; 389:133–134.

7. Dubos RJ, Pierce CH. Differential characteristics in vitro and in vivo of several substrains of BCG. I. Multiplication and survival in vitro. Am Rev Tuberc. 1956; 74:655–666.

8. Leung AS, Tran V, Wu Z, et al. Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genomics. 2008; 9:413.

9. Oettinger T, Jorgensen M, Ladefoged A, Haslov K, Andersen P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis. 1999; 79:243–250.

10. Liu J, Tran V, Leung AS, Alexander DC, Zhu B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin. 2009; 5:70–78.

11. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996; 178:1274–1282.

12. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999; 284:1520–1523.

13. Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole ST. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol. 1999; 32:643–655.

14. Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol. 2002; 46:709–717.

15. Hsu T, Hingley-Wilson SM, Chen B, et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A. 2003; 100:12420–12425.

16. Lewis KN, Liao R, Guinn KM, et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation. J Infect Dis. 2003; 187:117–123.

17. Majlessi L, Brodin P, Brosch R, et al. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J Immunol. 2005; 174:3570–3579.

18. Amoudy HA, Al-Turab MB, Mustafa AS. Identification of transcriptionally active open reading frames within the RD1 genomic segment of Mycobacterium tuberculosis. Med Princ Pract. 2006; 15:137–144.

19. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998; 393:537–544.

20. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology. 1998; 144(Pt 11):3195–3203.

21. Mustafa AS, Al-Attiyah R, Hanif SN, Shaban FA. Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells. Clin Vaccine Immunol. 2008; 15:916–924.

22. Okkels LM, Brock I, Follmann F, et al. PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. Infect Immun. 2003; 71:6116–6123.

23. Liu XQ, Dosanjh D, Varia H, et al. Evaluation of T-cell responses to novel RD1- and RD2-encoded Mycobacterium tuberculosis gene products for specific detection of human tuberculosis infection. Infect Immun. 2004; 72:2574–2581.

24. Millington KA, Fortune SM, Low J, et al. Rv3615c is a highly immunodominant RD1 (region of difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A. 2011; 108:5730–5735.

25. Li H, Ulstrup JC, Jonassen TO, Melby K, Nagai S, Harboe M. Evidence for absence of the MPB64 gene in some substrains of Mycobacterium bovis BCG. Infect Immun. 1993; 61:1730–1734.

26. Roche PW, Feng CG, Britton WJ. Human T-cell epitopes on the Mycobacterium tuberculosis secreted protein MPT64. Scand J Immunol. 1996; 43:662–670.

27. Mustafa T, Wiker HG, Morkve O, Sviland L. Reduced apoptosis and increased inflammatory cytokines in granulomas caused by tuberculous compared to non-tuberculous mycobacteria: role of MPT64 antigen in apoptosis and immune response. Clin Exp Immunol. 2007; 150:105–113.

28. Weldingh K, Andersen P. Immunological evaluation of novel Mycobacterium tuberculosis culture filtrate proteins. FEMS Immunol Med Microbiol. 1999; 23:159–164.

29. Chen J, Su X, Zhang Y, et al. Novel recombinant RD2- and RD11-encoded Mycobacterium tuberculosis antigens are potential candidates for diagnosis of tuberculosis infections in BCG-vaccinated individuals. Microbes Infect. 2009; 11:876–885.

30. Chen J, Wang S, Zhang Y, et al. Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls. BMC Infect Dis. 2010; 10:273.

31. Kalra M, Grover A, Mehta N, et al. Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clin Immunol. 2007; 125:173–183.

32. Wang C, Chen Z, Fu R, et al. A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice. Med Microbiol Immunol. 2011; 200:165–175.

33. Brosch R, Gordon SV, Buchrieser C, Pym AS, Garnier T, Cole ST. Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur. Yeast. 2000; 17:111–123.

34. Salazar L, Fsihi H, de Rossi E, et al. Organization of the origins of replication of the chromosomes of Mycobacterium smegmatis, Mycobacterium leprae and Mycobacterium tuberculosis and isolation of a functional origin from M. smegmatis. Mol Microbiol. 1996; 20:283–293.

35. Mehra S, Kaushal D. Functional genomics reveals extended roles of the Mycobacterium tuberculosis stress response factor sigmaH. J Bacteriol. 2009; 191:3965–3980.

36. Manganelli R, Voskuil MI, Schoolnik GK, Dubnau E, Gomez M, Smith I. Role of the extracytoplasmic-function sigma factor sigma(H) in Mycobacterium tuberculosis global gene expression. Mol Microbiol. 2002; 45:365–374.

37. Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007; 104:5596–5601.

38. Kernodle DS. Warning: differences in the copy number of duplication unit 2 (DU2) within BCG Danish 1331 may influence findings involving genetically modified BCG Danish strains. Vaccine. 2012; 30:6013–6014.

39. Wolucka BA, Communi D. Mycobacterium tuberculosis possesses a functional enzyme for the synthesis of vitamin C, L-gulono-1,4-lactone dehydrogenase. FEBS J. 2006; 273:4435–4445.

40. Alexander DC, Behr MA. Rv1773 is a transcriptional repressor deleted from BCG-Pasteur. Tuberculosis (Edinb). 2007; 87:421–425.

41. Honda I, Seki M, Ikeda N, et al. Identification of two subpopulations of Bacillus Calmette-Guerin (BCG) Tokyo172 substrain with different RD16 regions. Vaccine. 2006; 24:4969–4974.

42. Bedwell J, Kairo SK, Behr MA, Bygraves JA. Identification of substrains of BCG vaccine using multiplex PCR. Vaccine. 2001; 19:2146–2151.

43. Naka T, Maeda S, Niki M, et al. Lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain. J Biol Chem. 2011; 286:44153–44161.

44. Chen JM, Islam ST, Ren H, Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine. 2007; 25:8114–8122.

45. Mostowy S, Tsolaki AG, Small PM, Behr MA. The in vitro evolution of BCG vaccines. Vaccine. 2003; 21:4270–4274.

46. Manganelli R, Provvedi R, Rodrigue S, Beaucher J, Gaudreau L, Smith I. Sigma factors and global gene regulation in Mycobacterium tuberculosis. J Bacteriol. 2004; 186:895–902.

47. Heimbeck J. Tuberkuloseschutzmittel BCG, Prinzipien and Resultate. Schweiz Z Tuberk. 1949; 6:209–224.

48. Hyge TV. The efficacy of BCG-vaccination; epidemic of tuberculosis in a State School, with an observation period of 12 years. Acta Tuberc Scand. 1956; 32:89–107.

49. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271:698–702.

50. Gaisford W, Griffiths M. B.C.G. vaccination in the newborn; preliminary report. Br Med J. 1951; 2:702–705.

51. Cartwright JD. BCG vaccination of the newborn. S Afr Med J. 1978; 54:65–67.

52. Vallishayee RS, Shashidhara AN, Bunch-Christensen K, Guld J. Tuberculin sensitivity and skin lesions in children after vaccination with 11 different BCG strains. Bull World Health Organ. 1974; 51:489–494.

53. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ. 1990; 68:93–108.

54. Myint TT, Win H, Aye HH, Kyaw-Mint TO. Case-control study on evaluation of BCG vaccination of newborn in Rangoon, Burma. Ann Trop Paediatr. 1987; 7:159–166.

55. Zilber N, Simchen E, Wartski S, Marcus JH, Shakya GR. Effect of mass BCG vaccination at birth on the incidence of tuberculosis among Jewish children in Israel. Isr J Med Sci. 1984; 20:1150–1157.

56. Padungchan S, Konjanart S, Kasiratta S, Daramas S, ten Dam HG. The effectiveness of BCG vaccination of the newborn against childhood tuberculosis in Bangkok. Bull World Health Organ. 1986; 64:247–258.

57. Young TK, Hershfield ES. A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians. Am J Public Health. 1986; 76:783–786.

58. Tidjani O, Amedome A, ten Dam HG. The protective effect of BCG vaccination of the newborn against childhood tuberculosis in an African community. Tubercle. 1986; 67:269–281.

59. Jin BW, Hong YP, Kim SJ. A contact study to evaluate the BCG vaccination programme in Seoul. Tubercle. 1989; 70:241–248.

60. Ritz N, Curtis N. Mapping the global use of different BCG vaccine strains. Tuberculosis (Edinb). 2009; 89:248–251.

61. Yamamoto S, Yamamoto T. Historical review of BCG vaccine in Japan. Jpn J Infect Dis. 2007; 60:331–336.

62. Holm J. BCG vaccination in Denmark. Public Health Rep. 1946; 61:1298–1315.

63. Osborn TW. Serial subcultivation of Czechoslovakian and Japanese BCG strains. J Hyg (Lond). 1980; 85:235–246.